We found that COVID-19 plasma exosomes and LPS stimulated significant production of IL-6, IL-8, and TNF-α in CD3+ lymphocytes compared with those treated with non-COVID plasma exosomes, establishing that PBMC responded to COVID-19 plasma exosomes (Supplementary Fig. 1b,c). The gene discussed is CXCL8; the disease is COVID-19.